Apocrine carcinoma of the breast - Revision history

Michael at 11:38, 8 September 2016

2016-09-08T11:38:27Z

← Older revision		Revision as of 11:38, 8 September 2016
Line 14:		Line 14:
	\| IF =		\| IF =
	\| Gross =		\| Gross =
	\| Grossing = [[~~mastectomy~~ grossing]]		\| Grossing = [[breast grossing]]
	\| Staging = [[breast cancer staging]]		\| Staging = [[breast cancer staging]]
	\| Site = [[breast]] - see ''[[invasive breast cancer]]''		\| Site = [[breast]] - see ''[[invasive breast cancer]]''

Michael at 04:11, 1 May 2016

2016-05-01T04:11:29Z

← Older revision		Revision as of 04:11, 1 May 2016
Line 14:		Line 14:
	\| IF =		\| IF =
	\| Gross =		\| Gross =
	\| Grossing =		\| Grossing = [[mastectomy grossing]]
			\| Staging = [[breast cancer staging]]
	\| Site = [[breast]] - see ''[[invasive breast cancer]]''		\| Site = [[breast]] - see ''[[invasive breast cancer]]''
	\| Assdx =		\| Assdx =

Michael: /* IHC */

2016-02-10T01:17:10Z

IHC

← Older revision		Revision as of 01:17, 10 February 2016
Line 63:		Line 63:
	==IHC==		==IHC==
	Smaller tumours classically:<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>		Smaller tumours classically:<ref name=pmid16045781>{{Cite journal \| last1 = Honma \| first1 = N. \| last2 = Takubo \| first2 = K. \| last3 = Akiyama \| first3 = F. \| last4 = Sawabe \| first4 = M. \| last5 = Arai \| first5 = T. \| last6 = Younes \| first6 = M. \| last7 = Kasumi \| first7 = F. \| last8 = Sakamoto \| first8 = G. \| title = Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast. \| journal = Histopathology \| volume = 47 \| issue = 2 \| pages = 195-201 \| month = Aug \| year = 2005 \| doi = 10.1111/j.1365-2559.2005.02181.x \| PMID = 16045781 }}</ref>
	*AR +ve.		*[[Androgen receptor\|AR]] +ve.
	*[[GCDFP-15]] +ve.		*[[GCDFP-15]] +ve.
	Usually:<ref name=Ref_BP217>{{Ref BP\|217}}</ref>		Usually:<ref name=Ref_BP217>{{Ref BP\|217}}</ref>

Sarah: /* Microscopic */

2015-04-02T03:07:11Z

Microscopic

← Older revision		Revision as of 03:07, 2 April 2015
Line 38:		Line 38:
	==Microscopic==		==Microscopic==
	Features:<ref name=Ref_BP217>{{Ref BP\|217}}</ref>		Features:<ref name=Ref_BP217>{{Ref BP\|217}}</ref>
	*Prominent [[nucleoli]].		*Prominent red [[nucleoli]].
	**Often multiple.<ref>{{Cite journal \| last1 = O'Malley \| first1 = FP. \| last2 = Bane \| first2 = A. \| title = An update on apocrine lesions of the breast. \| journal = Histopathology \| volume = 52 \| issue = 1 \| pages = 3-10 \| month = Jan \| year = 2008 \| doi = 10.1111/j.1365-2559.2007.02888.x \| PMID = 18171412 }}</ref>		**Often multiple.<ref>{{Cite journal \| last1 = O'Malley \| first1 = FP. \| last2 = Bane \| first2 = A. \| title = An update on apocrine lesions of the breast. \| journal = Histopathology \| volume = 52 \| issue = 1 \| pages = 3-10 \| month = Jan \| year = 2008 \| doi = 10.1111/j.1365-2559.2007.02888.x \| PMID = 18171412 }}</ref>
	*Abundant granular eosinophilic cytoplasm.		*Abundant granular eosinophilic cytoplasm.

Michael: /* IHC */

2015-04-02T02:45:36Z

IHC

← Older revision		Revision as of 02:45, 2 April 2015
Line 70:		Line 70:
	*Often HER2 +ve but can be HER2 -ve.<ref name=pmid19898421>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>		*Often HER2 +ve but can be HER2 -ve.<ref name=pmid19898421>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>

	Notes		Notes:
	*Salivary ~~gland~~ carcinoma and cutaneous adnexal ~~tumors~~ can show a similar IHC profile.		*[[Salivary duct carcinoma]] and cutaneous adnexal tumours can show a similar IHC profile.
	*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' <ref>{{Cite journal \| last1 = Tsutsumi \| first1 = Y. \| title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. \| journal = Jpn J Clin Oncol \| volume = 42 \| issue = 5 \| pages = 375-86 \| month = May \| year = 2012 \| doi = 10.1093/jjco/hys034 \| PMID = 22450930 }}</ref>.		*Apocrine carcioma can be a non-basal type 'triple negative carcinoma'.<ref name=pmid22450930>{{Cite journal \| last1 = Tsutsumi \| first1 = Y. \| title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. \| journal = Jpn J Clin Oncol \| volume = 42 \| issue = 5 \| pages = 375-86 \| month = May \| year = 2012 \| doi = 10.1093/jjco/hys034 \| PMID = 22450930 }}</ref>
	**May show different behaviour to other types of triple negative carcinoma		**May show different behaviour to other types of triple negative carcinoma.
	**May respond to treatments targeting the androgen receptor<ref>{{Cite journal \| last1 = Safarpour \| first1 = D. \| last2 = Tavassoli \| first2 = FA. \| title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. \| journal = Arch Pathol Lab Med \| volume = \| issue = \| pages = \| month = Oct \| year = 2014 \| doi = 10.5858/arpa.2014-0122-RA \| PMID = 25310144 }}		**May respond to treatments targeting the androgen receptor.<ref name=pmid25310144>{{Cite journal \| last1 = Safarpour \| first1 = D. \| last2 = Tavassoli \| first2 = FA. \| title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. \| journal = Arch Pathol Lab Med \| volume = \| issue = \| pages = \| month = Oct \| year = 2014 \| doi = 10.5858/arpa.2014-0122-RA \| PMID = 25310144 }}</ref>
	</ref>
	*Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma.		*Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma.
	*Many ductal carcinomas, NOS ~~will~~ show AR positivity but are often ER +ve.		*Many [[invasive ductal carcinoma of the breast\|ductal carcinomas, NOS]] show AR positivity but are often ER +ve.

	==See also==		==See also==

Michael at 21:08, 1 April 2015

2015-04-01T21:08:25Z

← Older revision		Revision as of 21:08, 1 April 2015
Line 9:		Line 9:
	\| LMDDx = [[glycogen-rich clear cell carcinoma of the breast]]		\| LMDDx = [[glycogen-rich clear cell carcinoma of the breast]]
	\| Stains =		\| Stains =
	\| IHC = AR +ve, [[GCDFP-15]] +ve, ER -ve, PR -ve		\| IHC = AR +ve, [[GCDFP-15]] +ve, ER -ve, PR -ve, HER2 +ve/-ve
	\| EM =		\| EM =
	\| Molecular =		\| Molecular =
Line 47:		Line 47:
	*Cutaneous Apocrine Carcinoma		*Cutaneous Apocrine Carcinoma
	***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum.		***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum.
	*Apocrine-like carcinoma - immunoprolife doesn't fit for invasive AC (ER +ve, PR +ve, AR-ve).<ref name=pmid23245877/>		*Apocrine-like carcinoma - immunoprolife doesn't fit for invasive AC (ER +ve, PR +ve, AR -ve).<ref name=pmid23245877/>

	===Images===		===Images===

Michael: /* IHC */

2015-04-01T21:06:49Z

IHC

← Older revision		Revision as of 21:06, 1 April 2015
Line 68:		Line 68:
	*ER -ve.		*ER -ve.
	*PR -ve.		*PR -ve.
	*~~often~~ HER2 +ve but can be HER2 -ve<ref name=pmid19898421>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>		*Often HER2 +ve but can be HER2 -ve.<ref name=pmid19898421>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>

	Notes		Notes

Michael at 21:06, 1 April 2015

2015-04-01T21:06:15Z

← Older revision		Revision as of 21:06, 1 April 2015
Line 1:		Line 1:
	{{ Infobox diagnosis		{{ Infobox diagnosis
	\| Name = {{PAGENAME}}		\| Name = {{PAGENAME}}
	\| Image =		\| Image = Breast ApocrineCarcinoma MP2 CTR.jpg
	\| Width =		\| Width =
	\| Caption =		\| Caption = Apocrine carcinoma of the breast. [[H&E stain]].
	\| Synonyms =		\| Synonyms =
	\| Micro = apocrine morphology (cells with prominent [[nucleoli]] - may be multiple, abundant granular eosinophilic cytoplasm) - must be >=90% of tumour, loss of basal cells		\| Micro = apocrine morphology (cells with prominent [[nucleoli]] - may be multiple, abundant granular eosinophilic cytoplasm) - must be >=90% of tumour, loss of basal cells
Line 25:		Line 25:
	\| Rads =		\| Rads =
	\| Endoscopy =		\| Endoscopy =
	\| Prognosis =		\| Prognosis = poor, worse the ductal carcinoma
	\| Other =		\| Other =
	\| ClinDDx =		\| ClinDDx = other breast masses
	\| Tx =		\| Tx = excision
	}}		}}
	'''Apocrine carcinoma of the breast''' is a rare form of [[invasive breast cancer]].		'''Apocrine carcinoma of the breast''' is a rare form of [[invasive breast cancer]].
Line 34:		Line 34:
	==General==		==General==
	*Need >=90% apocrine morphology.<ref name=Ref_BP217>{{Ref BP\|217}}</ref>		*Need >=90% apocrine morphology.<ref name=Ref_BP217>{{Ref BP\|217}}</ref>
			*Worse prognosis that [[invasive ductal carcinoma of the breast]] in a large series.<ref name=pmid23245877>{{Cite journal \| last1 = Dellapasqua \| first1 = S. \| last2 = Maisonneuve \| first2 = P. \| last3 = Viale \| first3 = G. \| last4 = Pruneri \| first4 = G. \| last5 = Mazzarol \| first5 = G. \| last6 = Ghisini \| first6 = R. \| last7 = Mazza \| first7 = M. \| last8 = Iorfida \| first8 = M. \| last9 = Rotmensz \| first9 = N. \| title = Immunohistochemically defined subtypes and outcome of apocrine breast cancer. \| journal = Clin Breast Cancer \| volume = 13 \| issue = 2 \| pages = 95-102 \| month = Apr \| year = 2013 \| doi = 10.1016/j.clbc.2012.11.004 \| PMID = 23245877 }}</ref>

	==Microscopic==		==Microscopic==
Line 46:		Line 47:
	*Cutaneous Apocrine Carcinoma		*Cutaneous Apocrine Carcinoma
	***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum.		***A possible cutaneous apocrine carcinoma in a patient with a history of mammary apocrine carcinoma is problematic but fortunately a relatively infrequent conundrum.
			*Apocrine-like carcinoma - immunoprolife doesn't fit for invasive AC (ER +ve, PR +ve, AR-ve).<ref name=pmid23245877/>

	===Images===		===Images===
Line 66:		Line 68:
	*ER -ve.		*ER -ve.
	*PR -ve.		*PR -ve.
	*often ~~Her2~~ +ve but can be ~~Her2~~ -ve<ref>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>		*often HER2 +ve but can be HER2 -ve<ref name=pmid19898421>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>

	Notes		Notes

Sarah: /* IHC */

2015-04-01T12:00:50Z

IHC

← Older revision		Revision as of 12:00, 1 April 2015
Line 66:		Line 66:
	*ER -ve.		*ER -ve.
	*PR -ve.		*PR -ve.
	*often Her2 +ve but can be Her2 -ve		*often Her2 +ve but can be Her2 -ve<ref>{{Cite journal \| last1 = Niemeier \| first1 = LA. \| last2 = Dabbs \| first2 = DJ. \| last3 = Beriwal \| first3 = S. \| last4 = Striebel \| first4 = JM. \| last5 = Bhargava \| first5 = R. \| title = Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. \| journal = Mod Pathol \| volume = 23 \| issue = 2 \| pages = 205-12 \| month = Feb \| year = 2010 \| doi = 10.1038/modpathol.2009.159 \| PMID = 19898421 }}</ref>

	Notes		Notes

Sarah: /* IHC */

2015-04-01T11:58:40Z

IHC

← Older revision		Revision as of 11:58, 1 April 2015
Line 66:		Line 66:
	*ER -ve.		*ER -ve.
	*PR -ve.		*PR -ve.
	*often Her2 -ve		*often Her2 +ve but can be Her2 -ve

	Notes		Notes
	*Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile.		*Salivary gland carcinoma and cutaneous adnexal tumors can show a similar IHC profile.
	*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' ~~identified by both morphology and AR positivity~~<ref>{{Cite journal \| last1 = Tsutsumi \| first1 = Y. \| title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. \| journal = Jpn J Clin Oncol \| volume = 42 \| issue = 5 \| pages = 375-86 \| month = May \| year = 2012 \| doi = 10.1093/jjco/hys034 \| PMID = 22450930 }}</ref>.		*Apocrine carcioma can be a non-basal type 'triple negative carcinoma' <ref>{{Cite journal \| last1 = Tsutsumi \| first1 = Y. \| title = Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. \| journal = Jpn J Clin Oncol \| volume = 42 \| issue = 5 \| pages = 375-86 \| month = May \| year = 2012 \| doi = 10.1093/jjco/hys034 \| PMID = 22450930 }}</ref>.
	**May show different behaviour to other types of triple negative carcinoma		**May show different behaviour to other types of triple negative carcinoma
	**May respond to treatments targeting the androgen receptor<ref>{{Cite journal \| last1 = Safarpour \| first1 = D. \| last2 = Tavassoli \| first2 = FA. \| title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. \| journal = Arch Pathol Lab Med \| volume = \| issue = \| pages = \| month = Oct \| year = 2014 \| doi = 10.5858/arpa.2014-0122-RA \| PMID = 25310144 }}		**May respond to treatments targeting the androgen receptor<ref>{{Cite journal \| last1 = Safarpour \| first1 = D. \| last2 = Tavassoli \| first2 = FA. \| title = A Targetable Androgen Receptor-Positive Breast Cancer Subtype Hidden Among the Triple-Negative Cancers. \| journal = Arch Pathol Lab Med \| volume = \| issue = \| pages = \| month = Oct \| year = 2014 \| doi = 10.5858/arpa.2014-0122-RA \| PMID = 25310144 }}
	</ref>		</ref>
	**Be ~~carefull~~ when reading the literature in this area - is the author discussing 'molecular apocrine', ~~'IHC apocrine'~~ or 'morphologic apocrine' carcinoma. Many ductal carcinomas, NOS will show AR positivity.		*Be careful when reading the literature in this area - is the author discussing 'molecular apocrine' (ER -ve, AR +ve) or 'morphologic apocrine' carcinoma.
			*Many ductal carcinomas, NOS will show AR positivity but are often ER +ve.

	==See also==		==See also==